ESMO Breast 2020 | LILAC: comparing cardiac safety of ABP 980 with trastuzumab

Hans-Christian Kolberg, MD, PhD, of Marienhospital Bottrop, Bottrop, Germany, discusses LILAC, a randomized, double-blind, active-controlled study (NCT01901146) investigating the cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2+ early breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).